Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study)

Next Previous
X
Search
Trial Profile

A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ticagrelor (Primary) ; Aspirin
  • Indications Cardiovascular disorders; Myocardial infarction; Stroke
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms THEMIS
  • Sponsors AstraZeneca; AstraZeneca AB; AstraZeneca India

    • Most Recent Events

    • 06 Mar 2023 Results of post hoc analysis assessing the prevalence and prognostic impact of angina in the THEMIS trial, and whether if it modified the effect of ticagrelor on clinical events, presented at the 72nd Annual Scientific Session of the American College of Cardiology together with the World Heart Federation.
    • 26 Dec 2022 Results describing the proportion of patients eligible and reasons for ineligibility for THEMIS within a population of patients with diabetes and CAD, published in the International Journal of Cardiology
    • 29 Aug 2022 Results assessing the relationship between blood pressure components (including heart rate) and cardiovascular and bleeding events, and to determine if the effects of ticagrelor versus placebo varied across the blood pressure and heart rate spectrum, in patients with diabetes and stable coronary artery disease, presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top